The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation
Open accessAbstract
Summary of Key Recommendations: Diagnosis: It is recommended that the diagnosis of veno‐occlusive disease (sinusoidal obstruction syndrome) [VOD (SOS)] be based primarily on established clinical criteria (modified Seattle or Baltimore criteria) (1A). Ultrasound imaging may be helpful in the exclusion of other disorders in patients with suspected VOD (SOS) (1C). It is recommended that liver biopsy be reserved for patients in whom the diagnosis of VOD (SOS) is unclear and there is a need to exclude other diagnoses (1C). It is recommended that liver biopsies are undertaken using the transjugular approach in order to reduce the risks associated with the procedure (1C). It is suggested that the role of plasminogen activator inhibitor 1 levels remains an area for further research but that these levels should not form part of the routine diagnostic work‐up for VOD (SOS) at present (2C). Risk factors: It is recommended that patients are assessed for risk factors for VOD (SOS) and that these risk factors are addressed prior to haematopoietic stem cell transplantation (1A). Prophylaxis: Defibrotide is recommended at a dose of 6·25 mg/kg intravenously four times daily for the prevention of VOD (SOS) in children undergoing allogeneic stem cell transplantation with the following risk factors: pre‐existing hepatic disease, second myeloablative transplant, allogeneic transplant for leukaemia beyond second relapse, conditioning with busulfan‐containing regimens, prior treatment with gemtuzumab ozogamicin, diagnosis of primary haemophagocytic lymphohistiocytosis, adrenoleucodystrophy or osteopetrosis (1A). Defibrotide is suggested at a dose of 6·25 mg/kg intravenously four times daily for the prevention of VOD (SOS) in adults undergoing allogeneic stem cell transplantation with the following risk factors: pre‐existing hepatic disease, second myeloablative transplant, allogeneic transplant for leukaemia beyond second relapse, conditioning with busulfan‐containing regimens, prior treatment with gemtuzumab ozogamicin, diagnosis of primary haemophagocytic lymphohistiocytosis, adrenoleucodystrophy or osteopetrosis (2B). Prostaglandin E1 is not recommended in the prophylaxis of VOD (SOS) due to lack of efficacy and toxicity (1B). Pentoxifylline is not recommended in the prophylaxis of VOD (SOS) due to lack of efficacy (1A). Ursodeoxycholic acid is suggested for use in the prophylaxis of VOD (SOS) (2C). Heparin (unfractionated and low molecular weight) is not suggested for use in the prophylaxis of VOD (SOS) due to the risk of increased toxicity (2B). Antithrombin is not suggested for the prophylaxis of VOD (SOS) due to lack of efficacy (2B). Treatment: Defibrotide is recommended in the treatment of VOD (SOS) in adults and children (1B). Tissue plasminogen activator is not recommended for use in the treatment of VOD (SOS) due to the associated risk of haemorrhage (1B). N‐acetylcysteine is not routinely recommended for use in the treatment of veno‐occlusive disease due to lack of efficacy (1A). Methylprednisolone may be considered for use in the treatment of veno‐occlusive disease with the appropriate caveats of caution regarding infection (2C). Judicious clinical care, particularly in the management of fluid balance, is recommended in the management of VOD (SOS) (1C). Early discussion with critical care specialists and a specialist hepatology unit is recommended in the management of VOD (SOS) and other treatment options including transjugular intrahepatic portosystemic shunt or hepatic transplantation may be considered (1C). Summary: A joint working group established by the Haemato‐oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society for Blood and Marrow Transplantation (BSBMT) has reviewed the available literature and made recommendations for the diagnosis and management of veno‐occlusive disease of the liver following haematopoietic stem cell transplantation (HSCT). This guideline includes recommendations for both prophylaxis and treatment of the condition and includes recommendations for children and adults undergoing HSCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, G. B., Hinds, M. S., Fisher, L. D., Schoch, H. G., Wolford, J. L., Banaji, M., Hardin, B. J., Shulman, H. M., & Clift, R. A. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-4-199302150-00003 · Cited by 1,202
Vascular disorders of the liver # †
DeLeve, L. D., Valla, D.-C., & Garcia-Tsao, G. (2009) · Hepatology · doi:10.1002/hep.22772 · Cited by 978
VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION
JONES, R. J., LEE, K. S. K., BESCHORNER, W. E., VOGEL, V. G., GROCHOW, L. B., BRAINE, H. G., VOGELSANG, G. B., SENSENBRENNER, L. L., SANTOS, G. W., & SARAL, R. (1987) · Transplantation · doi:10.1097/00007890-198712000-00011 · Cited by 912
McDonald, G. B., Sharma, P. K., Matthews, D. E., Shulman, H. M., & Thomas, D. E. (1984) · Hepatology · doi:10.1002/hep.1840040121 · Cited by 845
Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)
DeLeve, L. D., Shulman, H. M., & McDonald, G. B. (2002) · Seminars in Liver Disease · doi:10.1055/s-2002-23204 · Cited by 664
Corbacioglu, S., Cesaro, S., Faraci, M., Valteau-Couanet, D., Gruhn, B., Rovelli, A., Boelens, J. J., Hewitt, A., Schrum, J., Schulz, A. S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61938-7 · Cited by 375
Self-citationCarter, T. (2003) · Scandinavian Journal of Work, Environment & Health · doi:10.5271/sjweh.1021 · Cited by 343
Carreras, E., Bertz, H., Arcese, W., Vernant, J., Tomás, J.-F., Hägglund, H., Bandini, G., Espérou, H., Russell, J., de la Rubia, J., et al. (1998) · PubMed · doi:10.1182/blood.v92.10.3599 · Cited by 343
Characterization of A Reproducible Rat Model of Hepatic Veno–Occlusive Disease
DeLeve, L. D., McCuskey, R. S., Wang, X., Hu, L., McCuskey, M. K., Epstein, R. B., & Kanel, G. C. (1999) · Hepatology · doi:10.1002/hep.510290615 · Cited by 324
Wadleigh, M., Richardson, P. G., Zahrieh, D., Lee, S. J., Cutler, C., Ho, V., Alyea, E. P., Antin, J. H., Stone, R. M., Soiffer, R. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0255 · Cited by 323
Cited by
Northup, P. G., Garcia‐Pagan, J. C., Garcia‐Tsao, G., Intagliata, N. M., Superina, R. A., Roberts, L. N., Lisman, T., & Valla, D. C. (2021) · Hepatology · doi:10.1002/hep.31646 · Cited by 667
FDA-Approved Oligonucleotide Therapies in 2017
Stein, C. A., & Castanotto, D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.023 · Cited by 608
Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.130 · Cited by 543
Self-citationCorbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J.-H., Dignan, F., Gibson, B., Guengoer, T., Gruhn, B., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.161 · Cited by 363
Self-citationDalle, J.-H., & Giralt, S. A. (2016) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.09.024 · Cited by 292
Metadata
- Authors
- Dignan, F. L., Wynn, R. F., Hadzic, N., Karani, J., Quaglia, A., Pagliuca, A., Veys, P., & Potter, M. N.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2013-09-17
- Volume
- 163
- Issue
- 4
- Pages
- 444-457
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2121599032
- Cited by
- 295
- References
- 59
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. https://app.cochat.ai/papers/10.1111/bjh.12558
- The paper
- Dignan, F. L., Wynn, R. F., Hadzic, N., Karani, J., Quaglia, A., Pagliuca, A., Veys, P., & Potter, M. N. (2013). BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.12558
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.